NZ630471A - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents

Extended-release formulation for reducing the frequency of urination and method of use thereof

Info

Publication number
NZ630471A
NZ630471A NZ630471A NZ63047113A NZ630471A NZ 630471 A NZ630471 A NZ 630471A NZ 630471 A NZ630471 A NZ 630471A NZ 63047113 A NZ63047113 A NZ 63047113A NZ 630471 A NZ630471 A NZ 630471A
Authority
NZ
New Zealand
Prior art keywords
extended
urination
frequency
reducing
release formulation
Prior art date
Application number
NZ630471A
Other languages
English (en)
Inventor
David A Dill
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Priority to NZ718163A priority Critical patent/NZ718163A/en
Priority to NZ712594A priority patent/NZ712594A/en
Priority to NZ714288A priority patent/NZ714288A/en
Publication of NZ630471A publication Critical patent/NZ630471A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ630471A 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof NZ630471A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
NZ718163A NZ718163A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ712594A NZ712594A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ714288A NZ714288A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2013/030901 WO2013142197A1 (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
NZ630471A true NZ630471A (en) 2016-04-29

Family

ID=49223209

Family Applications (6)

Application Number Title Priority Date Filing Date
NZ718163A NZ718163A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ630471A NZ630471A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ712594A NZ712594A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ714288A NZ714288A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ628079A NZ628079A (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ714662A NZ714662A (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ718163A NZ718163A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
NZ712594A NZ712594A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ714288A NZ714288A (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ628079A NZ628079A (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ714662A NZ714662A (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Country Status (15)

Country Link
EP (2) EP2827852A4 (ja)
JP (5) JP2015510928A (ja)
KR (4) KR20140134333A (ja)
CN (4) CN104302284A (ja)
AU (4) AU2013235518B2 (ja)
BR (2) BR112014020271A8 (ja)
CA (2) CA2866853A1 (ja)
HK (3) HK1251469A1 (ja)
MX (3) MX2014011128A (ja)
MY (2) MY174090A (ja)
NZ (6) NZ718163A (ja)
RU (3) RU2669565C2 (ja)
SG (2) SG11201500408VA (ja)
WO (2) WO2013142197A1 (ja)
ZA (2) ZA201405862B (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
KR20240015735A (ko) 2013-07-23 2024-02-05 세레니티 파마슈티컬즈 엘엘씨 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
RU2016152226A (ru) * 2014-06-06 2018-07-09 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения
KR101809908B1 (ko) 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
ES2923438T3 (es) * 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
SG11201805527QA (en) * 2015-09-30 2018-07-30 Wellesley Pharmaceuticals Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2546399A (en) * 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
EP1552825A4 (en) * 2002-06-07 2009-11-25 Astellas Pharma Inc THERAPEUTIC AGENT FOR THE TREATMENT OF VESIC HYPERACTIVITY
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
MXPA05010010A (es) * 2003-03-21 2006-03-10 Johnson & Johnson Regimen de dosificacion de farmaco anti-inflamatorio no-esteroideo.
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP2248524A3 (en) * 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
CA2612508A1 (en) * 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
AU2006284940B2 (en) * 2005-09-02 2012-03-22 Theravida, Inc. Therapy for the treatment of disease
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
RU2014142066A (ru) 2016-05-10
JP2016172752A (ja) 2016-09-29
AU2013235518A2 (en) 2014-10-09
CA2866755A1 (en) 2013-09-26
WO2013142197A1 (en) 2013-09-26
RU2669565C2 (ru) 2018-10-12
AU2017203246B2 (en) 2018-10-18
KR20170015537A (ko) 2017-02-08
KR20140134284A (ko) 2014-11-21
RU2014142025A (ru) 2016-05-10
AU2013235507A1 (en) 2014-08-21
RU2016133305A3 (ja) 2018-12-10
SG11201500409SA (en) 2015-03-30
EP2827851A1 (en) 2015-01-28
NZ718163A (en) 2017-09-29
RU2016133305A (ru) 2018-12-10
MX2014011128A (es) 2015-08-10
AU2017203139A1 (en) 2017-06-01
BR112014020113A2 (ja) 2017-06-20
AU2013235518A1 (en) 2014-09-25
KR20140134333A (ko) 2014-11-21
CN107157991A (zh) 2017-09-15
BR112014020271A8 (pt) 2017-07-11
RU2599017C2 (ru) 2016-10-10
MY175764A (en) 2020-07-08
CN107789626A (zh) 2018-03-13
JP2018024693A (ja) 2018-02-15
JP2015510928A (ja) 2015-04-13
AU2017203139B2 (en) 2018-07-19
JP2018138602A (ja) 2018-09-06
CA2866853A1 (en) 2013-07-26
EP2827852A1 (en) 2015-01-28
HK1204553A1 (en) 2015-11-27
MX2014011129A (es) 2015-08-10
NZ714662A (en) 2016-08-26
AU2013235507B2 (en) 2017-03-23
AU2013235518B2 (en) 2017-03-02
JP2015510936A (ja) 2015-04-13
EP2827852A4 (en) 2016-03-02
HK1243921A1 (zh) 2018-07-27
WO2013142274A1 (en) 2013-09-26
NZ714288A (en) 2016-12-23
CN104302284A (zh) 2015-01-21
EP2827851A4 (en) 2015-10-14
NZ628079A (en) 2016-05-27
KR20190003840A (ko) 2019-01-09
ZA201405862B (en) 2016-08-31
MY174090A (en) 2020-03-09
HK1251469A1 (zh) 2019-02-01
MX2019008817A (es) 2019-09-26
ZA201406146B (en) 2016-08-31
AU2017203246A1 (en) 2017-06-08
BR112014020271A2 (ja) 2017-06-20
CN104321056A (zh) 2015-01-28
BR112014020113A8 (pt) 2017-07-11
NZ712594A (en) 2016-09-30
SG11201500408VA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
NZ630471A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2014008283A (es) Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX2015000398A (es) Formulaciones de laquinimod sin agente alcalinizante.
IN2014MN02269A (ja)
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
GB201014391D0 (en) Drug composition and its use in therapy
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
IN2014DN10134A (ja)
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
ECSP12012332A (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
IN2014CN04119A (ja)
MX2014013083A (es) Composicion farmaceutica inyectable de dexketoprofeno y tramadol.
CO6630144A2 (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
IN2013MU02111A (ja)
IN2013MU02110A (ja)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2018 BY GRIFFITH HACK

Effective date: 20170207

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2019 BY GRIFFITH HACK

Effective date: 20180228

LAPS Patent lapsed